Home LiteratureArticle Details
PMID: 32657051 Published · ppublish English Journal Article Review

Testosterone, mood, behaviour and quality of life.

Andrology ·Vol. 8 ·No. 6 ·2020-00-00 ·Pages 1598-1605

Zitzmann M

Abstract

Testosterone plays a pivotal role in maintaining balance within the multi-dimensional psychological network of mood, behaviour, self-perception and perceived quality of life in men of any age. Apart from classical forms of hypogonadism, low testosterone concentrations can also be seen in older men, described as an age- and comorbidity-driven functional hypogonadism and might relate to depressive symptoms exhibiting a wide array of clinical pictures ranging from dysthymia and fatigue over inertia, listlessness to hopelessness and suicidal thoughts. Also, various traits of anxiety, from unfocussed fear to phobic anxiousness and open panic syndromes, are influenced by testosterone. Correspondingly, anxiolysis is likely to be modulated by testosterone via stress resilience, threat vigilance and reward processing. The steroid modulates pro-active and re-active dimensions of aggression, which has to be seen within the context of gaining or maintaining status. This may also include other strategies impacting the social position: heroic or parochial altruism and non-aggressive paths of assertiveness, such as posture and social vigilance. Independent rather than relationship-associated self-construal and self-esteem influence risk-taking traits under the modulation of testosterone. In addition, the genetic setting of the androgen receptor modulates the role of testosterone in aspects regarding mood and personality. Dimensions of sexuality are rather important in this context, but are not target of this article and covered in another part of this special edition. Overall, the quality of life in older hypogonadal men can be positively influenced by testosterone substitution, as has been demonstrated in large placebo-controlled trials.

Keywords
androgen receptor behaviour depression mood testosterone
MeSH Terms
Affect/drug effects Age of Onset Animals Behavior/drug effects Biomarkers/blood Hormone Replacement Therapy Humans Hypogonadism/blood,drug therapy,physiopathology,psychology Male Mental Health Quality of Life Receptors, Androgen/genetics,metabolism Testosterone/blood,deficiency,therapeutic use Testosterone Congeners/adverse effects
Chemicals
AR protein, human Biomarkers Receptors, Androgen Testosterone Congeners Testosterone
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Zitzmann Michael ORCID
Center for Reproductive Medicine and Andrology/Clinical Andrology, University Hospital, Münster, Germany.
References (76)
76 references, click to expand
  1. Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020.
  2. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S. EAU guidelines on male hypogonadism; 2018. https://uroweb.org/guideline/male-hypogonadism/?type=summary-of-changes. Accessed 04 Jun 2020
  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715-1744.
  4. Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry. 2005;66:7-14.
  5. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology. 2010;35:578-587.
  6. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry. 2011;19(3):274-283.
  7. Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-135.
  8. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the ‘androgen deprivation syndrome’ in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465-471.
  9. Olweus D, Mattsson A, Schalling D, et al. Testosterone, aggression, physical violence, and personality dimensions in normal adolescent males. Psychosom Med. 1980;42:253-269.
  10. Su T-P, Pagliaro M, Schmidt PJ, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA. 1993;269:2760-2764.
  11. Dabbs JM, Frady RL, Carr TS, Besch NF. Saliva testosterone and criminal violence in young adult prison inmates. Psychosom Med. 1987;49:174-182.
  12. Apicella CL, Dreber A, Mollerstrom J. Salivary testosterone change following monetary wins and losses predicts future financial risk-taking. Psychoneuroendocrinology. 2014;39:58-64.
  13. Carré JM, Campbell JA, Lozoya E, Goetz SMM, Welker KM. Changes in testosterone mediate the effect of winning on aggressive behavior. Psychoneuroendocrinology. 2013;38(10):2034-2041.
  14. Carré JM, Geniole SN, Ortiz TL, Bird BM, Videto A, Bonin PL. Exogenous testosterone rapidly increases aggressive behavior in dominant and impulsive men. Biol Psychiat. 2017;82(4):249-256.
  15. Welker KM, Norman R, Goetz SMM, Kitayama S, Carré JM. Preliminary evidence that testosterone’s association with aggressive behaviour depends on self-construal. Horm Behav. 2017;92:117-212.
  16. Mazur A, Booth A. Testosterone and dominance in men. Behav. Brain Sci. 1998;21:353-363; discussion 363-397.
  17. Higley JD, Mehlman PT, Poland RE, et al. CSF, testosterone and 5-HIAA correlate with different types of aggressive behaviors. Biol. Psychiatry. 1996;40:1067-1082.
  18. Eisenegger C, Haushofer J, Fehr E. The role of testosterone in social interaction. Trends Cogn Sci. 2011;15(6):263-271.
  19. Diekhof EK, Wittmer S, Reimers L. Does competition really bring out the worst? Testosterone, social distance and inter-male competition shape parochial altruism in human males. PLoS One. 2014;9(7):e98977.
  20. Reimers L, Kappo E, Stadler L, Yaqubi M, Diekhof EK. Endogenous testosterone correlates with parochial altruism in relation to costly punishment in different social settings. PeerJ. 2019;28(7):e7537.
  21. Reimers L, Büchel C, Diekhof EK. Neural substrates of male parochial altruism are modulated by testosterone and behavioral strategy. NeuroImage. 2017;1(156):265-276.
  22. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med. 1996;334:835-840.
  23. Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;16:e015284.
  24. Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry. 2014;26(1):19-32.
  25. Wu F, Zitzmann M, Heiselman D, et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. J Sex Med. 2016;13(8):1212-1219.
  26. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
  27. Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369-386.
  28. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10(6):1612-1627.
  29. Zitzmann M, Mattern A, Hanisch J, Looren L, Jones H, Maggi M. IPASS, a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2012;10:579-588.
  30. Rosen RC, Wu F, Behre HM, et al. Quality of life and sexual function benefits of long-term testosterone treatment: longitudinal results from the Registry of Hypogonadism in Men (RHYME). J Sex Med. 2017;14(9):1104-1115.
  31. Jockenhövel F, Minnemann T, Schubert M, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol. 2009;160(5):815-819.
  32. Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. Psychol Bull. 2017;143(8):783-822.
  33. Amiaz R, Seidman SN. Testosterone and depression in men. Curr Opin Endocrinol Diabetes Obes. 2008;15(3):278-283.
  34. Gould TD, Georgiou P, Brenner LA, et al. Animal models to improve our understanding and treatment of suicidal behavior. Transl Psychiatry. 2017;7(4):e1092.
  35. Carrier N, Saland SK, Duclot F, He H, Mercer R, Kabbaj M. The anxiolytic and antidepressant-like effects of testosterone and estrogen in gonadectomized male rats. Biol Psychiatry. 2015;78(4):259-269.
  36. Wainwright SR, Workman JL, Tehrani A, et al. Testosterone has antidepressant-like efficacy and facilitates imipramine-induced neuroplasticity in male rats exposed to chronic unpredictable stress. Horm Behav. 2016;79:58-69.
  37. Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast. 2007;2007:73754.
  38. Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. New Engl J Med. 2010;363(2):123-135.
  39. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression. J Clin Psychiatry. 2009;70(7):1009-1016.
  40. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7:2572-2582.
  41. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15:289-305.
  42. Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76:31-40.
  43. National Collaborating Centre for Mental Health UK. Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester, UK: British Psychological Society; 2010.
  44. Button KS, Kounali D, Thomas L, et al. Minimal clinically important difference on the Beck Depression Inventory-II according to the patient’s perspective. Psychol Med. 2015;45:3269-3279.
  45. Frye CA, Seliga A. Testosterone increases analgesia, anxiolysis, and cognitive performance of male rats. Cogn Affect Behav Neurosci. 2001;1:371-381.
  46. Aikey JL, Nyby JG, Anmuth DM, James PJ. Testosterone rapidly reduces anxiety in male house mice (Mus musculus). Horm Behav. 2002;42:448-460.
  47. Diamond P, Brisson G, Candas B, Peronnet F. Trait anxiety, submaximal physical exercise and blood androgens. Eur J Appl Physiol Occup Physiol. 1989;58:699-704.
  48. Granger DA, Shirtcliff EA, Zahnwaxler C, Usher B, Klimes-Dougan B, Hastings P. Salivary testosterone diurnal variation and psychopathology in adolescent males and females: Individual differences and developmental effects. Dev Psychopathol. 2003;15:431-449.
  49. Berglund LH, Prytz HS, Perski A, Svartberg J. Testosterone levels and psychological health status in men from a general population: The Tromsø study. Aging Male. 2011;14:37-41.
  50. Bandini E, Corona G, Ricca V, et al. Hysterical traits are not from the uterus but from the testis: A study in men with sexual dysfunction. J Sex Med. 2009;6:2321-2331.
  51. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Sex hormone levels, genetic androgen receptor polymorphism, and anxiety in ≥50-year-old males. J Sex Med. 2011;8:3452-3464.
  52. Geniole SN, Bird BM, McVittie JS, Purcell RB, Archer J, Carré JM. Is testosterone linked to human aggression? A meta-analytic examination of the relationship between baseline, dynamic, and manipulated testosterone on human aggression. Horm Behav. 2019;28:104644.
  53. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab. 2004;89(6):2837-2845.
  54. Geniole SN, Busseri MA, McCormick CM. Testosterone dynamics and psychopathic personality traits independently predict antagonistic behavior towards the perceived loser of a competitive interaction. Horm Behav. 2013;64:790-798.
  55. Cross SE, Hardin EE, Gercek-Swing B. The what, how, why, and where of self-construal. Pers Soc Psychol Rev. 2011;15(2):142-179.
  56. Welker KM, Roy ARK, Geniole S, Kitayama S, Carré JM. Taking risks for personal gain: An investigation of self-construal and testosterone responses to competition. Soc Neurosci. 2019;14(1):99-113.
  57. Bird BM, Geniole SN, Procyshyn TL, Ortiz TL, Carré JM, Watson NV. Effect of exogenous testosterone on cooperation depends on personality and time pressure. Neuropsychopharmacology. 2019;44:538-545.
  58. Geniole SN, Procyshyn TL, Marley N, et al. Using a psychopharmacogenetic approach to identify the pathways through which-and the people for whom-testosterone promotes aggression. Psychol Sci. 2019;30(4):481-494.
  59. Vermeersch H, T'Sjoen G, Kaufman JM, Vincke J, Van Houtte M. Testosterone, androgen receptor gene CAG repeat length, mood and behaviour in adolescent males. Eur J Endocrinol. 2010;163(2):319-328.
  60. Aluja A, García LF, Martí-Guiu M, et al. Interactions among impulsiveness, testosterone, sex hormone binding globulin and androgen receptor gene CAG repeat length. Physiol Behav. 2015;147:91-96.
  61. Eisenegger C, Kumsta R, Naef M, Gromoll J, Heinrichs M. Testosterone and androgen receptor gene polymorphism are associated with confidence and competitiveness in men. Horm Behav. 2017;92:93-102.
  62. Losecaat Vermeer AB, Krol I, Gausterer C, Wagner B, Eisenegger C, Lamm C. Exogenous testosterone increases status-seeking motivation in men with unstable low social status. Psychoneuroendocrinology. 2020;113:104552.
  63. Cohen J, Nassau DE, Patel P, Ramasamy R. Low testosterone in adolescents & young adults. Front Endocrinol (Lausanne). 2020;10(10):916.
  64. Salonia A, Rastrelli G, Hackett G, et al. Mohit Khera, Yee-Ming Chan, Mario Maggi. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019;5:38.
  65. McGinnis MY. Anabolic Androgenic Steroids and Aggression: Studies Using Animal Models. Ann N Y Acad Sci. 2004;1036:399-415.
  66. Williams R. Me and My Monkey, 2002. Song lyrics.
  67. Sansone A, Sansone M, Vaamonde D, et al. Sport, doping and male fertility. Reprod Biol Endocrinol. 2018;16(1):114.
  68. Sansone A, Sansone M, Lenzi A, Romanelli F. Testosterone replacement therapy: the Emperor's new clothes. Rejuvenation Res. 2017;20:9-14.
  69. Kanayama G, Pope HG, Hudson JI. Associations of anabolic-androgenic steroid use with other behavioral disorders: an analysis using directed acyclic graphs. Psychol. Med. 2018;48:2601-2608.
  70. Hall RCW, Hall RCW, Chapman MJ. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 2005;46:285-290.
  71. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur. Psychiatry. 2006;21:551-562.
  72. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur. Psychiatry. 2006;21:563-569.
  73. Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs. 2005;19:571-595.
  74. Lundholm L, Käll K, Wallin S, Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend. 2010;111(3):222-226.
  75. Vorona E, Nieschlag E. Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding. Minerva Endocrinol. 2018;43(4):476-488.
  76. Bertozzi G, Salerno M, Pomara C, Sessa F. Neuropsychiatric and behavioral involvement in AAS abusers. A literature review. Medicina (Kaunas). 2019;55:396.
Article Info
Journal
Andrology
Abbr.
Andrology
ISSN
2047-2927
DOI
10.1111/andr.12867
Published
2020-00-00
Epub
2020-00-30
Pages
1598-1605
Language
English
Region
England
NLM ID
101585129
Subset
IM
External Links
PubMed source DOI: 10.1111/andr.12867 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2